Skip to content

At the Breast Cancer Symposium held in San Antonio, Texas, in December, 2008, Chlebowski and colleagues [1] referred to correlated declines in the use of menopausal hormone therapy (HT) and the incidence of breast cancer, as reported in an analysis of the SEER database by Ravdin and colleagues [2], and they presented data from the Women’s Health Initiative (WHI) randomized, controlled trial (RCT) and observational study on changes in incidence following cessation of estrogen plus progestin (E + P) (RCT) or HT (observational study). In both WHI studies, the incidence of breast cancer declined following cessation of use, and the findings were interpreted as suggesting that ‘… cessation … is associated with a rapid reduction … [in breast cancer incidence] … which is not explained by mammography utilization change (sic) and [the findings] support the hypothesis that the recent reduction … seen in certain age groups is predominantly related to a decrease in menopausal therapy use (sic).’


  • Samuel Shapiro
    Department of Public Health and Family Medicine, University of Cape Town, South Africa
  • Anne Gompel
    Unité de Gynécologie Endocrinienne, Hôtel-Dieu de Paris, Université Paris Descartes, Paris, France


International Menopause Society

Install International Menopause Society - DEV

Install this application on your home screen for quick and easy access when you’re on the go.

Just tap then “Add to Home Screen”